Metoject Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA, RNA and protein synthesis. This action suppresses rapidly dividing immune cells and inflammatory pathways, providing therapeutic effects in autoimmune diseases and certain cancers.

The specific dose of Metoject Pen is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosing regimens vary widely, and the prescriber will tailor the amount and frequency to each individual case.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be discontinued well before conception. Use during breastfeeding is also discouraged, as the drug can be excreted in milk.

To request Metoject Pen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Metoject Pen offers a pre‑filled, subcutaneous delivery system that can improve patient convenience and dosing accuracy compared with oral tablets or traditional injectable vials. Subcutaneous administration often results in more consistent absorption and may reduce gastrointestinal side effects seen with oral methotrexate.

Metoject Pen should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the device in its original packaging until use to maintain stability and sterility.

Metoject Pen is a pre‑filled, single‑use pen designed for subcutaneous injection. After selecting the prescribed dose, the user removes the safety cap, places the needle against the skin (typically on the abdomen or thigh), and presses the plunger to deliver the medication. Training by a healthcare professional is recommended.

Serious risks include liver toxicity, pulmonary fibrosis, severe bone‑marrow suppression leading to pancytopenia, and teratogenic effects. Patients should be monitored regularly for liver enzymes, lung function and blood counts, and should avoid pregnancy throughout treatment and for a defined period after discontinuation.

Metoject Pen is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, severe renal or hepatic impairment, and patients with active infections that could be worsened by immunosuppression. Clinicians must evaluate each patient’s medical history before initiating therapy.